Silence Therapeutics plc (NasdaqGM: SLN)
Health Care · Biotechnology · GB
$13.29
+0.15% today · +148.0% 1Y
Silence Therapeutics plc (NasdaqGM: SLN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $798.98M and employs 88 people.
Over the last twelve months the share price has gained 148.0%, trading between 4.19 and 17.58.
Tweenvest scores Silence Therapeutics plc across four factors: quality 36/100, value 63/100, growth 84/100. Its strongest factor is growth.
SLN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $798.98M
- Revenue (TTM)
- $615.00K
- P/E
- —
- EPS
- -1.27
- Dividend yield
- —
- Beta (5Y)
- 1.41
- 52-week high
- $17.58
- 52-week low
- $4.19
- Avg volume (3M)
- —
- Shares outstanding
- 60.21M
- Employees
- 88
- Next earnings
- —
About Silence Therapeutics plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
- ISIN
- US82686Q1013
- Founded
- 1994
- Listed since
- Sep 8, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.